Journey Medical Corporation

NASDAQ:DERM

Drug Manufacturers - Specialty & Generic

Healthcare
$3.69 +0.99%

+$0.06 today

Market cap
$104.15M
Beta
1.10
P/E (TTM)
-17.0
EPS (TTM)
-$0.35
52W Low $4.31High $9.56

Volume 0.25M

Average 0.28M

DERM Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Journey Medical CorporationNASDAQ: DERM

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow declines year over year

Q1 FY2026 financing cash flow of $220K fell 93.9% year over year, behind the -31.8% change in trailing-twelve-month financing cash flow. Sequentially, it fell 96.0% from the prior quarter. Over 3 fiscal years it compounded at -0.5% a year.

Context

  • Financing cash flow amounted to 26.2% of revenue in FY2025, down 4.0 pp from a year earlier.
  • Financing cash flow increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -93.9% toward the trailing-twelve-month pace of -31.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$220K-96.0% QoQ
Last fiscal yearDec 2025
$16.23M-4.5% YoY
LTMMar 2026
$12.92M-31.8% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-93.9%——
1 year-4.5%——
3-year CAGR-0.5%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
16.23M USD
Year-over-year change
-4.5%
4-year CAGR
-25.6%

Financing Cash Flow vs competitors

How DERM compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -31.8% is the 7th highest of 10, against a peer median of +59.4%.
  • Financing cash flow amounts to 20.0% of revenue for DERM, versus a peer median of 236.0%.
DERM Competitors
Financing Cash Flow for DERM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HSDTSolana CompanyLTM Mar 2026$442.16M USD+4786.8%+192.9%4611.1%
IVAInventiva S.A.FY2025€232M EUR+59.4%+84.0%5175.1%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$94.16M USD+226.3%-5.1%287.7%
NYXHNyxoah S.A.LTM Mar 2026€38.51M EUR-50.0%—236.0%
MDWDMediWound Ltd.LTM Mar 2026$30.48M USD+54.5%-6.1%210.5%
FENCFennec Pharmaceuticals Inc.LTM Mar 2026$23.28M USD+292.0%+3.0%45.6%
OSUROraSure Technologies, Inc.LTM Mar 2026$22.27M USD+481.2%-83.6%19.7%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$15.64M USD-86.7%—881.2%
DERMJourney Medical CorporationLTM Mar 2026$12.92M USD-31.8%-0.5%20.0%
OGIOrganigram Global Inc.LTM Mar 2026CA$1.87M CAD-101.7%—0.7%
Peer median (excluding DERM) —+59.4%-1.1%236.0%

Competitors are the stored peer set for DERM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(43.99M)(29.63M)(3.85M)(14.67M)(11.43M)
Depreciation & Amortization2.56M4.37M3.86M3.42M4.72M
Deferred Income Tax1.57M0000
Stock-Based Compensation2.47M4.43M2.61M6.1M6.29M
Change in Working Capital14.71M6.19M(1.66M)(3.77M)(11.9M)
Accounts Receivables768K(5.38M)12.55M4.48M(19.34M)
Inventory(8.46M)1.74M3.95M(4.23M)4.81M
Accounts Payables21.71M14.34M(18.42M)(2.1M)(7.27M)
Other Working Capital686K(4.52M)262K(1.92M)9.91M
Other Non-Cash Items20.51M1.12M4.29M(211K)(123K)
Operating Cash Flow(2.18M)(13.53M)5.24M(9.13M)(12.44M)
Capital Expenditures(10M)(20M)(5M)(15M)0
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(10M)(20M)(5M)(15M)0
Debt Repayment5.05M16.9M(8.95M)8.7M15.73M
Common Stock Issued32.54M142K4.49M8.29M16.93M
Common Stock Repurchased0(371K)000
Dividends Paid00000
Other Financing Activities16.97M(214K)(350K)(50K)(16.43M)
Financing Cash Flow53.02M16.46M(4.8M)16.99M16.23M
Effect of Forex Changes00000
Net Change in Cash40.84M(17.08M)(4.56M)(7.13M)3.79M
Free Cash Flow(12.18M)(33.53M)240K(9.13M)(12.44M)

Journey Medical Corporation

NASDAQ:DERM

Intrinsic Alpha fair value

Locked

Current Price

$3.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.